These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11227673)

  • 41. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
    Lin Q; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):722-5. PubMed ID: 19874684
    [No Abstract]   [Full Text] [Related]  

  • 43. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment.
    Kirishima T; Okanoue T; Daimon Y; Itoh Y; Nakamura H; Morita A; Toyama T; Minami M
    J Hepatol; 2002 Aug; 37(2):259-65. PubMed ID: 12127432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
    Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
    J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.
    Perrillo R; Hann HW; Mutimer D; Willems B; Leung N; Lee WM; Moorat A; Gardner S; Woessner M; Bourne E; Brosgart CL; Schiff E
    Gastroenterology; 2004 Jan; 126(1):81-90. PubMed ID: 14699490
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of YMDD mutants using universal template real-time PCR.
    Wang RS; Zhang H; Zhu YF; Han B; Yang ZJ
    World J Gastroenterol; 2006 Feb; 12(8):1308-11. PubMed ID: 16534892
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Lamivudine therapy for chronic hepatitis B].
    Daikoku M; Koga M
    Nihon Rinsho; 2004 Aug; 62 Suppl 8():321-5. PubMed ID: 15453338
    [No Abstract]   [Full Text] [Related]  

  • 48. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report.
    Orlando R; Tosone G; Portella G; Veropalumbo E; D'Onofrio M; Piazza M
    Infection; 2008 Oct; 36(5):472-4. PubMed ID: 17962902
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw.
    Zöllner B; Petersen J; Schröter M; Laufs R; Schoder V; Feucht HH
    Lancet; 2001 Mar; 357(9260):934-5. PubMed ID: 11289355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy.
    Mutimer D; Pillay D; Cook P; Ratcliffe D; O'Donnell K; Dowling D; Shaw J; Elias E; Cane PA
    J Infect Dis; 2000 Feb; 181(2):713-6. PubMed ID: 10669360
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
    Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
    J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
    Feng B; Wei L; Chen M; Wang L
    Microbiol Res; 2008; 163(4):487-92. PubMed ID: 17317127
    [TBL] [Abstract][Full Text] [Related]  

  • 53. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
    Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
    J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off!
    Angus P; Locarnini S
    Antivir Ther; 2004 Apr; 9(2):145-8. PubMed ID: 15134176
    [No Abstract]   [Full Text] [Related]  

  • 57. Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.
    Ohishi W; Shirakawa H; Kawakami Y; Kimura S; Kamiyasu M; Tazuma S; Nakanishi T; Chayama K
    J Med Virol; 2004 Apr; 72(4):558-65. PubMed ID: 14981758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
    Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
    J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment.
    Lee CZ; Lee HS; Huang GT; Yang PM; Sheu JC
    World J Gastroenterol; 2006 Sep; 12(33):5301-5. PubMed ID: 16981258
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay.
    Lindh M; Hannoun C; Malmström S; Lindberg J; Norkrans G
    J Clin Microbiol; 2006 Jul; 44(7):2587-9. PubMed ID: 16825388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.